- IBDEI3IN ; ; 19-NOV-2015
- ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
- Q:'DIFQR(358.4) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
- Q Q
- ;;^UTILITY(U,$J,358.4,1694,0)
- ;;=SUBSEQUENT OBSERVATION CARE^10^152
- ;;^UTILITY(U,$J,358.4,1695,0)
- ;;=OBSERVATION CARE D/C SERVICES^11^152
- ;;^UTILITY(U,$J,358.4,1696,0)
- ;;=PROLONGED SERVICES^5^153
- ;;^UTILITY(U,$J,358.4,1697,0)
- ;;=VENOUS^6^153
- ;;^UTILITY(U,$J,358.4,1698,0)
- ;;=BP MONITORING^1^153
- ;;^UTILITY(U,$J,358.4,1699,0)
- ;;=MEDICATION^4^153
- ;;^UTILITY(U,$J,358.4,1700,0)
- ;;=CARDIOVASCULAR^2^153
- ;;^UTILITY(U,$J,358.4,1701,0)
- ;;=CATHETER^3^153
- ;;^UTILITY(U,$J,358.4,1702,0)
- ;;=HEMODIALYSIS-ESRD^13^154
- ;;^UTILITY(U,$J,358.4,1703,0)
- ;;=PERITONEAL DIALYSIS ENCOUNTER^22^154
- ;;^UTILITY(U,$J,358.4,1704,0)
- ;;=CARDIOLOGY/CARDIORENAL SYNDROME^2^154
- ;;^UTILITY(U,$J,358.4,1705,0)
- ;;=COMPLICATIONS/OTHER^4^154
- ;;^UTILITY(U,$J,358.4,1706,0)
- ;;=CYSTIC KIDNEY DISEASE^5^154
- ;;^UTILITY(U,$J,358.4,1707,0)
- ;;=DIABETES/DIABETIC RENAL DISEASE^6^154
- ;;^UTILITY(U,$J,358.4,1708,0)
- ;;=FLUID/ELECTROLYTE DISORDER^7^154
- ;;^UTILITY(U,$J,358.4,1709,0)
- ;;=GENERAL SYMPTOMS^8^154
- ;;^UTILITY(U,$J,358.4,1710,0)
- ;;=GENITAL/URINARY^9^154
- ;;^UTILITY(U,$J,358.4,1711,0)
- ;;=HEMATOLOGY^11^154
- ;;^UTILITY(U,$J,358.4,1712,0)
- ;;=HYPERTENSION^14^154
- ;;^UTILITY(U,$J,358.4,1713,0)
- ;;=INFECTIOUS DISEASE^15^154
- ;;^UTILITY(U,$J,358.4,1714,0)
- ;;=NEPHRITIS GLUMERULONEPHRITIS^17^154
- ;;^UTILITY(U,$J,358.4,1715,0)
- ;;=NEPHRITIS INTERSTITIAL^18^154
- ;;^UTILITY(U,$J,358.4,1716,0)
- ;;=NEPHROTIC SYNDROME^20^154
- ;;^UTILITY(U,$J,358.4,1717,0)
- ;;=OBSTRUCTIVE UROPATHY^21^154
- ;;^UTILITY(U,$J,358.4,1718,0)
- ;;=TRANSPLANT^24^154
- ;;^UTILITY(U,$J,358.4,1719,0)
- ;;=CKD/KIDNEY DISEASE^3^154
- ;;^UTILITY(U,$J,358.4,1720,0)
- ;;=HEMODIALYSIS-AKI^12^154
- ;;^UTILITY(U,$J,358.4,1721,0)
- ;;=ACUTE KIDNEY INJURY^1^154
- ;;^UTILITY(U,$J,358.4,1722,0)
- ;;=GLOMERULAR DISEASE^10^154
- ;;^UTILITY(U,$J,358.4,1723,0)
- ;;=KIDNEY INVOLVMNT IN SYSTEMIC DISEASE^16^154
- ;;^UTILITY(U,$J,358.4,1724,0)
- ;;=NEPHROLITHASIS^19^154
- ;;^UTILITY(U,$J,358.4,1725,0)
- ;;=POISONING & INTOXICATIONS^23^154
- ;;^UTILITY(U,$J,358.4,1726,0)
- ;;=ESTABLISHED PATIENT^1^155
- ;;^UTILITY(U,$J,358.4,1727,0)
- ;;=CONSULTATIONS/OPINIONS^2^155
- ;;^UTILITY(U,$J,358.4,1728,0)
- ;;=NEW PATIENTS^3^155
- ;;^UTILITY(U,$J,358.4,1729,0)
- ;;=NEUROLOGY/SEIZURE^7^156
- ;;^UTILITY(U,$J,358.4,1730,0)
- ;;=EEG^4^156
- ;;^UTILITY(U,$J,358.4,1731,0)
- ;;=SLEEP TESTING^9^156
- ;;^UTILITY(U,$J,358.4,1732,0)
- ;;=MUSCLE TESTING/EMG^6^156
- ;;^UTILITY(U,$J,358.4,1733,0)
- ;;=EVOKED POTENTIAL^5^156
- ;;^UTILITY(U,$J,358.4,1734,0)
- ;;=BIOPSY^2^156
- ;;^UTILITY(U,$J,358.4,1735,0)
- ;;=AUTONOMIC FUNCTION TESTS^1^156
- ;;^UTILITY(U,$J,358.4,1736,0)
- ;;=STEREOTACTIC^10^156
- ;;^UTILITY(U,$J,358.4,1737,0)
- ;;=EDUCATION^3^156
- ;;^UTILITY(U,$J,358.4,1738,0)
- ;;=NEUROSTIMULATORS^8^156
- ;;^UTILITY(U,$J,358.4,1739,0)
- ;;=SEIZURES/EPILEPSY/SPELLS^14^157
- ;;^UTILITY(U,$J,358.4,1740,0)
- ;;=CEREBROVASCULAR DISEASE^2^157
- ;;^UTILITY(U,$J,358.4,1741,0)
- ;;=DIZZINESS^3^157
- ;;^UTILITY(U,$J,358.4,1742,0)
- ;;=ENCEPHALOPATHY^5^157
- ;;^UTILITY(U,$J,358.4,1743,0)
- ;;=HEADACHE^6^157
- ;;^UTILITY(U,$J,358.4,1744,0)
- ;;=MOVEMENT DISORDERS^8^157
- ;;^UTILITY(U,$J,358.4,1745,0)
- ;;=NEOPLASMS^9^157
- ;;^UTILITY(U,$J,358.4,1746,0)
- ;;=NEURODEGENERATIVE DISEASE^10^157
- ;;^UTILITY(U,$J,358.4,1747,0)
- ;;=OTHER^12^157
- ;;^UTILITY(U,$J,358.4,1748,0)
- ;;=CARDIAC DISORDERS^1^157
- ;;^UTILITY(U,$J,358.4,1749,0)
- ;;=INFLAMMATORY & DEMYELINATING DISEASES^7^157
- ;;^UTILITY(U,$J,358.4,1750,0)
- ;;=NEUROMUSCULAR DISORDERS^11^157
- ;;^UTILITY(U,$J,358.4,1751,0)
- ;;=PAIN^13^157
- ;;^UTILITY(U,$J,358.4,1752,0)
- ;;=SPINAL CONDITIONS^15^157
- ;;^UTILITY(U,$J,358.4,1753,0)
- ;;=SYMPTOMS^16^157
- --- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI3IN 3962 printed Feb 19, 2025@00:15:56 Page 2
- IBDEI3IN ; ; 19-NOV-2015
- +1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
- +2 if 'DIFQR(358.4)
- QUIT
- FOR I=1:2
- SET X=$TEXT(Q+I)
- if X=""
- QUIT
- SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
- SET X=$EXTRACT(X,4,999)
- if $ASCII(Y)=126
- SET I=I+1
- SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,99)
- if $ASCII(Y)=61
- SET Y=$EXTRACT(Y,2,999)
- XECUTE NO
- IF '$TEST
- SET @X=Y
- Q QUIT
- +1 ;;^UTILITY(U,$J,358.4,1694,0)
- +2 ;;=SUBSEQUENT OBSERVATION CARE^10^152
- +3 ;;^UTILITY(U,$J,358.4,1695,0)
- +4 ;;=OBSERVATION CARE D/C SERVICES^11^152
- +5 ;;^UTILITY(U,$J,358.4,1696,0)
- +6 ;;=PROLONGED SERVICES^5^153
- +7 ;;^UTILITY(U,$J,358.4,1697,0)
- +8 ;;=VENOUS^6^153
- +9 ;;^UTILITY(U,$J,358.4,1698,0)
- +10 ;;=BP MONITORING^1^153
- +11 ;;^UTILITY(U,$J,358.4,1699,0)
- +12 ;;=MEDICATION^4^153
- +13 ;;^UTILITY(U,$J,358.4,1700,0)
- +14 ;;=CARDIOVASCULAR^2^153
- +15 ;;^UTILITY(U,$J,358.4,1701,0)
- +16 ;;=CATHETER^3^153
- +17 ;;^UTILITY(U,$J,358.4,1702,0)
- +18 ;;=HEMODIALYSIS-ESRD^13^154
- +19 ;;^UTILITY(U,$J,358.4,1703,0)
- +20 ;;=PERITONEAL DIALYSIS ENCOUNTER^22^154
- +21 ;;^UTILITY(U,$J,358.4,1704,0)
- +22 ;;=CARDIOLOGY/CARDIORENAL SYNDROME^2^154
- +23 ;;^UTILITY(U,$J,358.4,1705,0)
- +24 ;;=COMPLICATIONS/OTHER^4^154
- +25 ;;^UTILITY(U,$J,358.4,1706,0)
- +26 ;;=CYSTIC KIDNEY DISEASE^5^154
- +27 ;;^UTILITY(U,$J,358.4,1707,0)
- +28 ;;=DIABETES/DIABETIC RENAL DISEASE^6^154
- +29 ;;^UTILITY(U,$J,358.4,1708,0)
- +30 ;;=FLUID/ELECTROLYTE DISORDER^7^154
- +31 ;;^UTILITY(U,$J,358.4,1709,0)
- +32 ;;=GENERAL SYMPTOMS^8^154
- +33 ;;^UTILITY(U,$J,358.4,1710,0)
- +34 ;;=GENITAL/URINARY^9^154
- +35 ;;^UTILITY(U,$J,358.4,1711,0)
- +36 ;;=HEMATOLOGY^11^154
- +37 ;;^UTILITY(U,$J,358.4,1712,0)
- +38 ;;=HYPERTENSION^14^154
- +39 ;;^UTILITY(U,$J,358.4,1713,0)
- +40 ;;=INFECTIOUS DISEASE^15^154
- +41 ;;^UTILITY(U,$J,358.4,1714,0)
- +42 ;;=NEPHRITIS GLUMERULONEPHRITIS^17^154
- +43 ;;^UTILITY(U,$J,358.4,1715,0)
- +44 ;;=NEPHRITIS INTERSTITIAL^18^154
- +45 ;;^UTILITY(U,$J,358.4,1716,0)
- +46 ;;=NEPHROTIC SYNDROME^20^154
- +47 ;;^UTILITY(U,$J,358.4,1717,0)
- +48 ;;=OBSTRUCTIVE UROPATHY^21^154
- +49 ;;^UTILITY(U,$J,358.4,1718,0)
- +50 ;;=TRANSPLANT^24^154
- +51 ;;^UTILITY(U,$J,358.4,1719,0)
- +52 ;;=CKD/KIDNEY DISEASE^3^154
- +53 ;;^UTILITY(U,$J,358.4,1720,0)
- +54 ;;=HEMODIALYSIS-AKI^12^154
- +55 ;;^UTILITY(U,$J,358.4,1721,0)
- +56 ;;=ACUTE KIDNEY INJURY^1^154
- +57 ;;^UTILITY(U,$J,358.4,1722,0)
- +58 ;;=GLOMERULAR DISEASE^10^154
- +59 ;;^UTILITY(U,$J,358.4,1723,0)
- +60 ;;=KIDNEY INVOLVMNT IN SYSTEMIC DISEASE^16^154
- +61 ;;^UTILITY(U,$J,358.4,1724,0)
- +62 ;;=NEPHROLITHASIS^19^154
- +63 ;;^UTILITY(U,$J,358.4,1725,0)
- +64 ;;=POISONING & INTOXICATIONS^23^154
- +65 ;;^UTILITY(U,$J,358.4,1726,0)
- +66 ;;=ESTABLISHED PATIENT^1^155
- +67 ;;^UTILITY(U,$J,358.4,1727,0)
- +68 ;;=CONSULTATIONS/OPINIONS^2^155
- +69 ;;^UTILITY(U,$J,358.4,1728,0)
- +70 ;;=NEW PATIENTS^3^155
- +71 ;;^UTILITY(U,$J,358.4,1729,0)
- +72 ;;=NEUROLOGY/SEIZURE^7^156
- +73 ;;^UTILITY(U,$J,358.4,1730,0)
- +74 ;;=EEG^4^156
- +75 ;;^UTILITY(U,$J,358.4,1731,0)
- +76 ;;=SLEEP TESTING^9^156
- +77 ;;^UTILITY(U,$J,358.4,1732,0)
- +78 ;;=MUSCLE TESTING/EMG^6^156
- +79 ;;^UTILITY(U,$J,358.4,1733,0)
- +80 ;;=EVOKED POTENTIAL^5^156
- +81 ;;^UTILITY(U,$J,358.4,1734,0)
- +82 ;;=BIOPSY^2^156
- +83 ;;^UTILITY(U,$J,358.4,1735,0)
- +84 ;;=AUTONOMIC FUNCTION TESTS^1^156
- +85 ;;^UTILITY(U,$J,358.4,1736,0)
- +86 ;;=STEREOTACTIC^10^156
- +87 ;;^UTILITY(U,$J,358.4,1737,0)
- +88 ;;=EDUCATION^3^156
- +89 ;;^UTILITY(U,$J,358.4,1738,0)
- +90 ;;=NEUROSTIMULATORS^8^156
- +91 ;;^UTILITY(U,$J,358.4,1739,0)
- +92 ;;=SEIZURES/EPILEPSY/SPELLS^14^157
- +93 ;;^UTILITY(U,$J,358.4,1740,0)
- +94 ;;=CEREBROVASCULAR DISEASE^2^157
- +95 ;;^UTILITY(U,$J,358.4,1741,0)
- +96 ;;=DIZZINESS^3^157
- +97 ;;^UTILITY(U,$J,358.4,1742,0)
- +98 ;;=ENCEPHALOPATHY^5^157
- +99 ;;^UTILITY(U,$J,358.4,1743,0)
- +100 ;;=HEADACHE^6^157
- +101 ;;^UTILITY(U,$J,358.4,1744,0)
- +102 ;;=MOVEMENT DISORDERS^8^157
- +103 ;;^UTILITY(U,$J,358.4,1745,0)
- +104 ;;=NEOPLASMS^9^157
- +105 ;;^UTILITY(U,$J,358.4,1746,0)
- +106 ;;=NEURODEGENERATIVE DISEASE^10^157
- +107 ;;^UTILITY(U,$J,358.4,1747,0)
- +108 ;;=OTHER^12^157
- +109 ;;^UTILITY(U,$J,358.4,1748,0)
- +110 ;;=CARDIAC DISORDERS^1^157
- +111 ;;^UTILITY(U,$J,358.4,1749,0)
- +112 ;;=INFLAMMATORY & DEMYELINATING DISEASES^7^157
- +113 ;;^UTILITY(U,$J,358.4,1750,0)
- +114 ;;=NEUROMUSCULAR DISORDERS^11^157
- +115 ;;^UTILITY(U,$J,358.4,1751,0)
- +116 ;;=PAIN^13^157
- +117 ;;^UTILITY(U,$J,358.4,1752,0)
- +118 ;;=SPINAL CONDITIONS^15^157
- +119 ;;^UTILITY(U,$J,358.4,1753,0)
- +120 ;;=SYMPTOMS^16^157
